You just read:

Sangamo Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II

News provided by

Sangamo Therapeutics, Inc.

Nov 15, 2017, 01:10 ET